|
 The Center of Molecular Immunology’s main mission is to
obtain and produce new biopharmaceutical products used in
the treatment of cancer and other chronic non
transmissible diseases and introduce them in the Cuban
Public Healthcare System. Make the scientific and
productive activities economically sustainable and
contribute to the economy of the country.
On December 5th,
1994 on the west side of Havana the Center of Molecular
Immunology is inaugurated. For the design and construction
of the Center of Molecular Immunology the current Good
Manufacturing Practices Guidelines adopted by Cuba and
recommended by the World Health Organization were used
particularly those adopted also by the countries member of
the European Community.
The new building is
basically two floor facility of over 15,000 square meters.
In the Center of
Molecular Immunology work approximately 400 employees,
most of them scientists and engineers. These personnel are
administratively organized in three main areas: Research
and Development, Production and Quality Assurance.
Today CIM produces
Biopharmaceutical products, such as: an anti CD3
monoclonal antibody for the treatment of patients with
organ transplant rejection, human recombinant
Erythropoietin for the treatment of anemia, granulocyte
Colony Stimulating Factor for the treatment of neutropenia,
a humanized monoclonal antibody that recognizes the
epidermal growth factor receptor for cancer treatment as
well as other monoclonal antibodies for tumor imaging.
|
